EURONanoMed

JOINT TRANSNATIONAL CALL FOR PROPOSALS (JTC2021) FOR “EUROPEAN INNOVATIVE RESEARCH & TECHNOLOGICAL DEVELOPMENT PROJECTS IN NANOMEDICINE”

GUIDELINES FOR APPLICANTS

DEADLINES
January 21st 2021 (17:00, CET) - SUBMISSION OF PRE-PROPOSALS
June 10th 2021 (17:00, CEST) - SUBMISSION OF INVITED FULL-PROPOSALS

Link to electronic proposal submission
https://ptoutline.eu/app/euronanomed2021
The submission system will be open by December 9th, 2020

JOINT CALL SECRETARIAT 2021

JCS 2021 is hosted by the National Institute of Health Carlos III
Monforte de Lemos, 5
28029 Madrid, SPAIN

Astrid Valencia Quiñónez
ma.valencia@isciii.es
Tel. + 34 91 822 2227
www.euronanomed.net
# Table of content

- Background .................................................................................................................. 3
- Registration .................................................................................................................... 3
- Building your proposal ................................................................................................. 3
- Proposal submission ..................................................................................................... 4
- Annex 1: Contact Point list .......................................................................................... 7
- Annex 2: INFORMATION FOR APPLICANTS NATIONAL ELIGIBILITY CRITERIA .......... 8
  - BELGIUM (French speaking community) .................................................................... 8
  - BULGARIA ................................................................................................................... 9
  - CZECH REPUBLIC ....................................................................................................... 11
  - EGYPT .......................................................................................................................... 11
  - ESTONIA ...................................................................................................................... 18
  - FRANCE ....................................................................................................................... 19
  - ISRAEL .......................................................................................................................... 21
  - ITALY ............................................................................................................................ 23
  - LATVIA ........................................................................................................................ 26
  - LITHUANIA .................................................................................................................. 28
  - POLAND ....................................................................................................................... 30
  - ROMANIA ..................................................................................................................... 32
  - SLOVAKIA ..................................................................................................................... 33
  - SPAIN (CDTI) .............................................................................................................. 35
  - SPAIN (ISCIII) .............................................................................................................. 38
  - TAIWAN ....................................................................................................................... 42
  - TURKEY ........................................................................................................................ 44
- Annex 3: Technology readiness levels (TRL) ................................................................. 48
- Annex 4: Guidelines for Responsible Research and Innovation (RRI) in proposals to EuroNanoMed III ................................................................. 49
BACKGROUND
Under the umbrella of EuroNanoMed III (ERA-NET Cofund for research programmes on nanomedicine), 17 funding organisations have agreed to launch the 12th Joint Transnational Call for collaborative innovative research projects in nanomedicine. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals. Please read the Call text for further details.

REGISTRATION
Research project consortia who intend to submit a transnational proposal should register at https://ptoutline.eu/app/euronanomed2021, clicking the “sign up” button and following the directions. The system will be opened by December 9th, 2020. To register, please complete the different sections as soon as possible.

BUILDING YOUR PROPOSAL
Please find a few references that could be helpful:

- Find potential partners:
  - Look at the Nanomedicine Map on ETPN website to. Please check if you are included in the map. You could easily include your group and contact details to be found by other consortia in preparation
  - Use the EuroNanoMed partnering tool
  - The Enterprise Europe Network

- Facilities and services at European level that you could contact:
  - The European Nanocharacterization Lab EU-NCL
  - Nanomedicine pilots funded by EU:
    - Nanofacturing is a multiple-scale, manufacturing platform to scale up of glycan-coated gold nanoparticles
    - Nanopilot project, a Pilot Plant for the Production of Polymer-based Nanopharmaceuticals in Compliance with Good Manufacturing Practices (GMP)
  - Apply to the Healthtech Translation Advisory Board for free of charge expert’s support
  - European Network of Pilot Production Facilities with SMEs Startups and Large enterprises (EPP)
  - European Research Infrastructures:
    - Clinical Research Infrastructure Network (ECRIN)
    - European Infrastructure for Translational Medicine (EATRIS)
- Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)
- The European Life Sciences Infrastructure for Biological Information (ELIXIR)
- The European Research Infrastructure for Imaging Technologies in Biological and Biomedical Sciences (Euro Bioimaging)
- European Infrastructure for Phenotyping, Archiving and Distribution of Mouse Models (INFRAFRONTIER)

Please visit the main Responsible Research and Innovation (RRI) sites:
- EuroNanoMed RRI Guidelines
- EU Guidelines for RRI in H2020
- The EU NanoSafety Cluster

Helpdesk for Intellectual Property Rights issues: https://www.iprhelpdesk.eu/

Guidelines on FAIR Data Management in Horizon 2020.

PROPOSAL SUBMISSION

Please read carefully the Call Text and the relevant central and national/regional eligibility and budgetary criteria (see Annexes) before starting your proposal in order to check if you fulfil the call’s formal requirements.

There will be a two-steps submission and evaluation procedure for joint applications: pre-proposals and full proposals. In both cases, one joint proposal document (in English) shall be prepared by the partners of a joint transnational proposal, and must be submitted by one spokesperson, the coordinator, to the JCS by uploading it on the electronic submission system: https://ptoutline.eu/app/euronanomed2021

The electronic submission system will be available from December 9th, 2020.

Please use the proposal templates (for pre- and full proposals) provided on the EuroNanoMed website (www.euronanomed.net) and complete all fields and respect the format of each section. Only the proposal template will be accepted. Please keep in mind that the templates have a fixed maximum size. Thus, the proposal document cannot be longer than the number of pages indicated in the proposal templates (DIN-A4, Calibri 11, single-spaced). In addition, the proposal in a digitally signed PDF-Format file (with a scanned version of the original signature page) to be
uploaded to the online tool must not exceed 8 Megabytes. Proposals exceeding these limitations will be rejected by the online system.

Deadline to submit pre-proposals: **January 21st, 2021 (17:00, CET)**
Deadline to submit full proposals: **June 10th, 2021 (17:00, CEST)**

After these deadlines, the server will not accept proposals and it will not be possible to amend the proposal or to add further documents.

Please take into account that the online data entry may be overloaded by the day of the deadline. It is therefore recommended to complete the registration and upload the proposal in proper time.

In case of inconsistencies between the information registered in the submission tool and the information included in the PDF of this application form, the information registered in the submission tool shall prevail.

For applicants from some countries/regions it might be also necessary to submit the proposal and/or other information, in some cases before the deadline of this call, directly to the relevant national/regional funding organisations. Therefore, applicants are strongly advised to check their respective country/region funding organisation eligibility and other specific information (see tables below). For more details, applicants may also get in touch with the respective funding organisations Contact Persons (see below). For central and additional information, you can contact the Joint Call Secretariat (JCS) at:

**National Institute of Health Carlos III**
Astrid Valencia Quiñónez
ma.valencia@isciii.es
Tel. +34 91 822 2227
Please Note:

It is mandatory to meet the deadline and the format of the proposal structure. The Joint Call Secretariat will check the proposals submitted to ensure that they meet the call’s formal criteria (e.g. date of submission; number of participating member states, category of project partners (academic, clinical/public health and industrial/SMEs), inclusion of all necessary information in English and appropriate limits on length). In parallel, the Joint Call Secretariat will forward the proposals to the relevant national/regional funding organisations that will perform a formal check of compliance with their respective eligibility criteria. Proposals not meeting the formal central and /or national/regional eligibility criteria will be rejected. Proposals passing both checks will be forwarded to independent international scientific experts for evaluation.

Potential project consortium coordinators are recommended to read the EuroNanoMed funding organisations’ eligibility criteria when they are looking for potential project consortium partners.

Project partners are strongly advised to read the specific eligibility criteria of the relevant funding organisations and other requirements and to contact their respective Contact Persons prior to submitting the application (see "Contact Point List" and "Information for Applicants" below).
## ANNEX 1: CONTACT POINT LIST

<table>
<thead>
<tr>
<th>Country</th>
<th>Funding Organisation</th>
<th>Contact point</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belgium</td>
<td>FRS-FNRS</td>
<td>Joël Groeneveld</td>
<td><a href="mailto:joel.groeneveld@frs-fnrs.be">joel.groeneveld@frs-fnrs.be</a></td>
</tr>
<tr>
<td>Bulgaria</td>
<td>BNSF</td>
<td>Milena Aleksandrova</td>
<td><a href="mailto:aleksandrova@mon.bg">aleksandrova@mon.bg</a></td>
</tr>
<tr>
<td>Czech Republic</td>
<td>TACR</td>
<td>Kristina Nehilčová</td>
<td><a href="mailto:kristina.nehilcova@tacr.cz">kristina.nehilcova@tacr.cz</a></td>
</tr>
<tr>
<td>Egypt</td>
<td>ASRT</td>
<td>Amr Radwan</td>
<td><a href="mailto:radwan.amro@gmail.com">radwan.amro@gmail.com</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Salma Essawi</td>
<td><a href="mailto:esalma2010@gmail.com">esalma2010@gmail.com</a></td>
</tr>
<tr>
<td>Estonia</td>
<td>ETAg</td>
<td>Argo Soon</td>
<td><a href="mailto:argo.soon@etag.ee">argo.soon@etag.ee</a></td>
</tr>
<tr>
<td>France</td>
<td>ANR</td>
<td>Martine Batoux</td>
<td><a href="mailto:ENMCalls@anr.fr">ENMCalls@anr.fr</a></td>
</tr>
<tr>
<td>Israel</td>
<td>CSO-MOH</td>
<td>Irit Allon</td>
<td><a href="mailto:Irit.allon@moh.gov.il">Irit.allon@moh.gov.il</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Orly Spivak</td>
<td><a href="mailto:orlee.f@gmail.com">orlee.f@gmail.com</a></td>
</tr>
<tr>
<td>Italy</td>
<td>IMH</td>
<td>Maria Grazia Mancini</td>
<td><a href="mailto:mg.mancini-esterno@sanita.it">mg.mancini-esterno@sanita.it</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><a href="mailto:research.eu.dgric@sanita.it">research.eu.dgric@sanita.it</a></td>
</tr>
<tr>
<td>Latvia</td>
<td>VIAA</td>
<td>Linda Vecbiškena</td>
<td><a href="mailto:Linda.Vecbiskena@viaa.gov.lv">Linda.Vecbiskena@viaa.gov.lv</a></td>
</tr>
<tr>
<td>Lithuania</td>
<td>RCL</td>
<td>Živilė Ruželė</td>
<td><a href="mailto:zivile.ruzele@lmt.lt">zivile.ruzele@lmt.lt</a></td>
</tr>
<tr>
<td>Poland</td>
<td>NCBR</td>
<td>Marcin Chmielewski</td>
<td><a href="mailto:Marcin.Chmielewski@ncbr.gov.pl">Marcin.Chmielewski@ncbr.gov.pl</a></td>
</tr>
<tr>
<td>Romania</td>
<td>UEFISCDI</td>
<td>Mihaela Manole</td>
<td><a href="mailto:mihaela.manole@uefiscdi.ro">mihaela.manole@uefiscdi.ro</a></td>
</tr>
<tr>
<td>Slovakia</td>
<td>SAS</td>
<td>Katarina BIBOVA</td>
<td><a href="mailto:bibova@up.upsav.sk">bibova@up.upsav.sk</a></td>
</tr>
<tr>
<td>Spain</td>
<td>ISCIII</td>
<td>Astrid Valencia Quiñonez</td>
<td><a href="mailto:ma.valencia@isciii.es">ma.valencia@isciii.es</a></td>
</tr>
<tr>
<td>Spain</td>
<td>CDTI</td>
<td>Marina Sopeña Escalona</td>
<td><a href="mailto:marina.sopena@cdti.es">marina.sopena@cdti.es</a></td>
</tr>
<tr>
<td>Taiwan</td>
<td>MOST</td>
<td>Ching-Mei Tang</td>
<td><a href="mailto:cmtom@most.gov.tw">cmtom@most.gov.tw</a></td>
</tr>
<tr>
<td>Turkey</td>
<td>TUBITAK</td>
<td>Dr. Mahmut Özer</td>
<td><a href="mailto:mahmut.ober@tubitak.gov.tr">mahmut.ober@tubitak.gov.tr</a></td>
</tr>
</tbody>
</table>
## ANNEX 2: INFORMATION FOR APPLICANTS NATIONAL ELIGIBILITY CRITERIA

### BELGIUM (FRENCH SPEAKING COMMUNITY)

<table>
<thead>
<tr>
<th>Funding Organisation</th>
<th>Fonds de la Recherche Scientifique – FNRS (F.R.S.-FNRS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial funding pre-commitment</td>
<td>The maximum amount of requested funding per project is <strong>200,000 EUR</strong> for a total period of three years. If the project involves the recruitment of a PhD student, the project duration of the F.R.S.-FNRS sub-project could be up to four years.</td>
</tr>
<tr>
<td>National Contact Point for the 12th call of ENM</td>
<td>Joël Groeneveld, Senior Policy Officer, <a href="mailto:joel.groeneveld@frs-fnrs.be">joel.groeneveld@frs-fnrs.be</a>, +32 2 504 9270</td>
</tr>
<tr>
<td>Additional requirement</td>
<td>Applicants to F.R.S.-FNRS funding must provide basic administrative data by submitting an administrative application on e-space (<a href="https://e-space.frs-fnrs.be/login">https://e-space.frs-fnrs.be/login</a>) within 5 working days after the general deadline of the EuroNanomed III JTC2021 call to be eligible. Please select the “PINT-MULTI” funding instrument when creating the administrative application. Proposals invited to the second stage will be able to complete the pre-proposal form and provide information for the full proposal upon validation by the F.R.S.-FNRS. The F.R.S.-FNRS will only fund regular research projects that last for 3 years.</td>
</tr>
<tr>
<td>Eligible costs</td>
<td>All eligibility rules and criteria can be found in the PINT-MULTI regulations.</td>
</tr>
</tbody>
</table>
## BULGARIA

<table>
<thead>
<tr>
<th>Funding Organisation</th>
<th>Bulgarian National Science Fund (BNSF)</th>
</tr>
</thead>
</table>
| **Initial funding pre-commitment** | Up to € 230,081/450,000 BGN  
Up to € 76,693/150,000 BGN per project  
3 projects tentatively envisaged to be funded |
| **National Contact Point for the 12TH call of ENM** | Name: Milena Aleksandrova  
Phone: +359 884 171 363  
e-mail: aleksandrova@mon.bg |
| **Eligible institutions** | 1) Accredited universities as defined in Art.85 para.1, p. 7 of the Higher Education Act;  
2) Research organizations as defined in Art. 47, para 1 of the Higher Education Act.  
[http://lll.mon.bg/uploaded_files/zkn_visseto_obr_01.03.2016_EN.pdf](http://lll.mon.bg/uploaded_files/zkn_visseto_obr_01.03.2016_EN.pdf) |
| **Additional requirement** | Applicants under this procedure shall be directly responsible for the implementation of the activities under the project proposal and shall not act as intermediaries, but they shall carry out activities under the project proposal on their behalf and at their expense.  
Applicants to this procedure must be entities:  
- Carrying out fundamental research studies; and  
- Whose activities are entirely of a non-profit nature; or  
- Whose activities are of both for-profit and not-for-profit nature, but these activities are clearly distinguished and their organization allows tracking of revenue and expenditures connected with their implementation, including by keeping analytical accounting. In the event that an applicant is involved in both for-profit and not-for-profit activities, the funding, expenditures and revenues shall be taken into account separately for each type of activity and on the basis of consistently applied principles of accounting of expenditures being justifiable. |
### Eligible costs

Eligible costs are specified in “National requirements and eligibility conditions” of Bulgarian National Science Fund available at:


### Further guidance

Applicants have to submit an application form for national eligibility when submitting the proposals. The formulier, entitled “Administrative description of the project” should be filled in both Bulgarian and in English and signed. Application forms can be obtained at:

[https://www.fni.bg/?q=node/578](https://www.fni.bg/?q=node/578)

They have to be sent back by post or in person to BNSF Registry Office before the deadline of 1st stage proposal submission.
### CZECH REPUBLIC

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial funding pre-commitment</td>
<td>€ 750,000</td>
</tr>
</tbody>
</table>
| National Contact Point for the 12TH call of ENM | Name: Kristina Nehilčová, Project Manager  
Phone: +420 234 611 629  
e-mail: kristina.nehilcova@tacr.cz |
| Eligible institutions        | 1) Enterprises (according to Annex 1 of [the Regulation](https://www.europa.eu/))  
2) Research organizations (according to Article 2 paragraph 83 of [the Regulation](https://www.europa.eu/))  
TACR excludes the disbursement of individual aid to an enterprise:  
- against which, following the decision of the European Commission under which the funding received from a provider from the Czech Republic was declared as illegal and incompatible with the internal market, a recovery order has been issued which is unpaid,  
- meeting the definition of an “[enterprise in difficulties](https://www.europa.eu/)(only in Czech)” referred to in Article 2(18) of [the Regulation](https://www.europa.eu/),  
- which has not met the obligation to publish the [financial statements for the years 2017, 2018, 2019](https://www.europa.eu/) in the relevant register - the so-called “Veřejný rejstřík”. |
| Additional requirement       | Type of supported research: applied research (i.e. industrial research / experimental development). For definitions of applied research see [the Framework](https://www.europa.eu/) and [the Regulation](https://www.europa.eu/).  
The maximum permissible aid intensity for the Czech part of the project is [85 %](https://www.europa.eu/) of eligible costs. The aid intensity for each Czech candidate in the project is determined based on the type of entity and type of research according to [the Regulation](https://www.europa.eu/) (see table below). |

---

Czech applicants are requested to submit:
- Sworn statement of the applicant;
- TACR Application Form Excel file;
- if the applicant plans to achieve the “NmetS” type of result, the “Confirmation of the Certification authority for NmetS results” needs to be attached;
- if the applicant plans to achieve the “Patent” type of result, patent search must be substantiated.

All documents proving the eligibility of the Czech partner stated above are available on TACR's website and shall be submitted via the TACR data box (TACR data box ID: afth9xp) within the same deadline as a project pre-proposals. Please fill in the subject line as: „Horizon2020 – EuroNanoMed 3 Call 2021 - prokázání způsobilosti - project acronym“.

TA CR will check following eligibility criteria at the national level:
- the project meets the definition of applied research
- the aim of the project is relevant to the overall aim of the EPSILON programme
- the research results correspond to the national rules (see below) and are applicable / exploitable (the project proposal has to include a clear description of the exploitation plan and results)
- the industrial research and experimental development share corresponds to the activities of the Czech partner as described in the project proposal
- the applicants are eligible
- the costs are eligible
- the requested funding meets the national regulations for aid intensity (see below)
- the applicants have published the financial statements for the requested years 2017, 2018, 2019

Czech applicants will be financed from the “EPSILON” Programme - subprogramme 2: “Energetika a materiály.” Relevance to the programme/subprogramme objectives is examined as a part of the eligibility check.
### Supported results

Projects that achieve at least one of the following types of results can be supported in this Call. The type of the result has to be clearly described in the project proposal:

- **P** - patent;
- **G** - technically realized results - prototype, functional sample;
- **Z** - pilot plant, proven technology;
- **R** - software;
- **F** - results with legal protection - utility model, industrial design;
- **N** - Certified methodologies and practices, treatment, conservation methods, procedures and specialized maps with professional expert content;
- **O** - Miscellaneous

Results not to be recognized as a single result of a given project, but only in combination with at least one other result listed in the list of result types above:

- **H** - results reflected in non-legislative directives and regulations binding within the competence of the respective provider and results reflected in the approved strategic and conceptual documents of the state or public administration.

Czech candidates are obliged to sign an agreement with their foreign partners (i.e. Consortium Agreement), which will define the modalities of cooperation on the project and the distribution of intellectual property rights.

Please note that following the national legislation, Czech applicants must start within 120 days from the funding decision being communicated by the Call Management (60-day period to make a contract + 60-day period to start the project).

### Eligible costs

**Budget & eligible costs**

The eligible costs are:

- personnel costs (including scholarships)
- subcontracting costs (max. 20% of total eligible costs throughout the whole project period)
- other direct costs (write-offs, protection of intellectual property, operating expenses, travel costs)
- indirect costs (overheads) - full cost/flat rate 25% (indirect costs in the respective year are calculated as 25% of the sum of the personnel costs and other direct costs in the same year)

These specific categories of eligible costs are defined under Article 17 of the General Terms & Conditions.

Investment costs are NOT eligible in this joint call.

The costs for clinical testing (including the Phase I.) are NOT eligible. Only the costs for pre-clinical testing are eligible.

**Please note:** TA CR will fund only the topic "Diagnostics" and "Targeted delivery systems".

**Funding rates**

The aid intensity for each Czech applicant in the project is determined based on the type of entity according to the Regulation (see table below) and at the same time must not exceed the maximum permissible aid intensity for the Czech part of the project, which is **85 % of the total eligible costs.**

<table>
<thead>
<tr>
<th>Beneficiary</th>
<th>small enterprise*</th>
<th>medium enterprise*</th>
<th>large enterprise*</th>
<th>research organization**</th>
<th>organisational unit of the state</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activity category</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Industrial research</strong></td>
<td>70 %</td>
<td>60 %</td>
<td>50 %</td>
<td>100 %</td>
<td>100 %</td>
</tr>
<tr>
<td><strong>Industrial research in case of effective cooperation</strong>*</td>
<td>80 %</td>
<td>75 %</td>
<td>65 %</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Experimental development</strong></td>
<td>45 %</td>
<td>35 %</td>
<td>25 %</td>
<td>100 %</td>
<td>100 %</td>
</tr>
</tbody>
</table>
### Guidelines for applicants JTC2021

<table>
<thead>
<tr>
<th>Experimental development in case of effective cooperation***</th>
<th>60 %</th>
<th>50 %</th>
<th>40 %</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>

* An SME is defined in Article 2 paragraph 2 and Annex 1 of the Regulation; a large enterprise is defined in Article 2 paragraph 24 of the Regulation.

** A research organization is defined under Article 2 paragraph 83 of the Regulation. The indicated funding rate is intended for non-economic activities of the research organisations (see also items 19 and 20 of the Framework).

*** Effective cooperation - the aid can be increased by up to 15% if the applicant fulfills the conditions according to the Regulation Article 25.

### Further guidance

Useful links:
- **TA CR International Calls**
- **EPSILON programme** (in Czech)
- **TACR Partnering Tool**
- **Definitions of supported outcomes** (in Czech)

*The Guide for Czech Applicants and Funding rules for the Czech applicant for ERA-NET cofunds* will be available on the TA CR website in Czech.

---

**Guidelines for applicants JTC2021**

## Egypt

| **Funding Organisation** | Academy of Scientific Research and Technology, (ASRT)  
| | Funding program: PRISM (National Program for research & innovation in biomedical sciences and health research) |
| **Initial funding pre-commitment** | 0.4 Mio. €  
| | Maximum ASRT funding for Egyptian entities Per Proposal:  
| | 1-125, 000 Euro for a proposal with Egyptian partner(s) in a consortium  
| | 2-150,000 Euro If Egyptian Partner is the coordinator of the project |
| **National Contact Point for the 12TH call of ENM** | Amr Radwan, Radwan.Amro@gmail.com, innov@sti.sci.eg  
| | Salma Essawi, esalma2010@gmail.com |
| **Eligible institutions** | This call is open to Egyptian legal entities established and based in Egypt. The Egyptian partner could be: research institutes, academic, non-academic organizations including NGOs and innovation agencies, industry, with special attention to small-medium size enterprises (SMEs). |
| **Additional requirement** | Egyptian legal entities established and based in Egypt.  
| | Egyptian PI must not have more than two ongoing projects funded by the Academy.  
<p>| | The Egyptian Team must follow the National regulation for the Academy of scientific research and technology Bylaws. |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Eligible costs include Staff remunerations, Equipment, Publication, Consumables, kits, laboratory chemicals, materials and other relevant costs directly attributable to the project, Travel costs and Costs for professional or technical services</td>
</tr>
<tr>
<td></td>
<td>• Total personnel costs must not exceed 25% of the total budget.</td>
</tr>
<tr>
<td></td>
<td>• Personnel costs for public employees; (technical support staff, researcher/lecturer, assistant professor and professor) shall not exceed 4000, 6000, 7000 and 8000 Egyptian pounds, respectively. For non-public employees (i.e consultants, marketing specialists, legal experts) personnel costs can exceed the abovementioned figures and it has to be documented according to required expertise and number of working hours.</td>
</tr>
<tr>
<td></td>
<td>• In the case of a participant participating in another ongoing publicly funded project, the allocated personnel cost in the proposal shall be decreased with 25% if participating in one additional project, 50% if participating in two other projects. In all cases, public employees at universities and research institutions can’t participate in 3 running projects.</td>
</tr>
</tbody>
</table>
## ESTONIA

| Funding Organisation | Eesti Teadusagentuur (Estonian Research Council)  
www.etag.ee |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial funding</td>
<td>100,000 €</td>
</tr>
<tr>
<td>pre-commitment</td>
<td>1 project tentatively envisaged to be funded.</td>
</tr>
</tbody>
</table>
| National Contact Point for the 12\textsuperscript{th} call of ENM | Dr Argo Soon, e-mail Argo.Soon@etag.ee  
Department of International Research Cooperation |
| Eligible institutions | The Host Institution must be registered and located in Estonia. R&D institutions must conform to the Organisation of Research and Development Act. For enterprises, subsection 3(2) of the Organisation of Research and Development Act does not apply. |
| Additional requirement | The Estonian Research Council (hereinafter ETAg) funds basic and applied research. Applied research is only funded as far as it does not refer to product development with commercial value and for marketing purposes. |
| Eligible costs       | Detailed requirements are on ETAg’s Website    |
FRANCE

<table>
<thead>
<tr>
<th>Funding Organisation</th>
<th>Agence Nationale de la Recherche (ANR); <a href="http://www.agence-nationale-recherche.fr">http://www.agence-nationale-recherche.fr</a></th>
</tr>
</thead>
</table>
| Initial funding pre-commitment | 2.500.000 €  
Anticipated number of funded research groups: ~12 |
| National Contact Point for the 12\textsuperscript{TH} call of EuroNanoMed | Dr. Martine Batoux  
email: ENMCalls@anr.fr; Phone : +33 (0)1 73 54 81 40  
Health & Biology Department; Agence Nationale de la Recherche –ANR; 50, avenue Daumesnil - 75012 Paris, France |
| Eligible institutions | Eligible institutions:  
- Public research organisations such as EPST, EPIC, universities, university hospitals, public research institutes (max. rate of support: 100% of marginal costs, except for an EPIC involved in a consortium with an enterprise. See [https://www.agence-nationale-recherche.fr/RF for more details](https://www.agence-nationale-recherche.fr/RF)).  
- Enterprises: large & SMEs (max. rate of support: 45% of total costs for SMEs & 30% for larger companies). Other type of organisations may be eligible. Please consult [https://www.agence-nationale-recherche.fr/RF for more details](https://www.agence-nationale-recherche.fr/RF). |
| Additional eligibility criteria | - The coordinator (if from a French institution) must belong to a public research organisation.  
- ANR does not allow double funding and will not finance projects or parts of projects that have been funded through other ANR calls or by other funders.  
ANR will cross-check the proposals submitted to ANR through the national and international calls for possible demands of double funding. |
| Eligible costs | The ANR funding regulations apply [https://www.agence-nationale-recherche.fr/RF](https://www.agence-nationale-recherche.fr/RF)  
Personnel, Consumables, subcontracting (up to 50% of the requested budget per partner), Small Equipment, Travel.  
Please see [https://www.agence-nationale-recherche.fr/RF](https://www.agence-nationale-recherche.fr/RF) for full reference. |
<table>
<thead>
<tr>
<th>Guidelines for applicants JTC2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Please note that « overheads » correspond to « frais généraux—frais d’environnement» in the ANR funding regulations, and that applicable rates vary based on the partner’s category. Please see <a href="http://www.agence-nationale-recherche.fr/RF">http://www.agence-nationale-recherche.fr/RF</a> point 3.1.1.e/ for full reference. ANR has a maximum funding per partner for this call: each research team can be funded with a maximum amount of 200 000 €. A coordinator of a project can be funded with a maximum of 250 000 €.</td>
</tr>
<tr>
<td>Further guidance</td>
</tr>
<tr>
<td>RULE FOR SELECTED PROPOSALS (if an industrial partner is involved in the project): A copy of the signed consortium agreement established between the consortium partners must be provided to ANR within the first 6 months of the project. Please see online the specific annex document for research partners applying to this call for proposals for funding in France: <a href="http://www.anr.fr/Euronanomed-2021">http://www.anr.fr/Euronanomed-2021</a></td>
</tr>
</tbody>
</table>
## ISRAEL

| Funding organisation                          | Chief Scientist office, Ministry of Health (CSO-MOH)  
|                                              | http://www.health.gov.il/ |
| National contact person                      | Dr. Irit Allon  
| Phone: +972 (0)2 5082167 ; Email: irit.allon@moh.health.gov.il |
| Chief Scientist Office, Ministry of Health |
| Orly Spivak                                  | Phone: +972 (0) 526314326; Email: orlee.f@gmail.com |
| Chief Scientist Office, Ministry of Health  |

| Funding commitment                          | Up to 3000,000 €, depending on budget availability |
| Anticipated number of fundable research groups | Up to 2 projects |
| Maximum funding per grant awarded to a partner | Up to 140,000 €  
| Additional 20,000 € for coordination |
| Eligibility of project duration             | Up to 3 years |
| Eligibility of a partner as a beneficiary institution | Position in a university, research center or hospital. Research authority must approve position prior to submission. |
| Eligibility of principal investigator or other research team member | PI should hold a Ph.D., M.D., D.M.D., D. Sc or equivalent degree and employed by an eligible institution. Research will not be funded simultaneously by CSO-MOH on more than one grant (Era-NET or national). Researchers can not apply for more than one grant from any ERA-NET funded by CSO-MOH or submit more than one proposal for any programme. |
| Eligibility of costs, types and their caps | Materials and consumables; Travel and hosting (up to 10%); No salaries for applicants; No heavy equipment, Institutional overhead 10%. |
| Submission of the proposal at the national level | Prior to submission, researchers will submit to CSO-MOH an abstract approved by their research authority including budget distribution. No submission of abstract can result in declaration of the consortium as ineligible. |
| Submission of other information at the national level | If the application involves human or animal experiments, bioethics approvals must be submitted with the application or up to 4 months later. |
| Submission of financial and scientific reports at the national level | Required annually. |
| Further guidance | Please see detailed instructions of application at the national level and reporting at [http://www.health.gov.il/research-fund](http://www.health.gov.il/research-fund) |
### ITALY

<table>
<thead>
<tr>
<th>Country</th>
<th>ITALY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding organisation</td>
<td>IMH - Ministry of Health (<a href="http://www.salute.gov.it">www.salute.gov.it</a>)</td>
</tr>
<tr>
<td>National Contact Point for the 12th call of EuroNanoMed</td>
<td>Directorate General for Health Research and Innovation Ministry of Health – Ministero della Salute Office 3 Viale Giorgio Ribotta, 5 00144 Rome, Italy Email: <a href="mailto:research.eu.dgric@sanita.it">research.eu.dgric@sanita.it</a>; Phone: +39 06.5994.3215 Maria Grazia Mancini (Email: <a href="mailto:mg.mancini-esterno@sanita.it">mg.mancini-esterno@sanita.it</a>; <a href="mailto:research.eu.dgric@sanita.it">research.eu.dgric@sanita.it</a>)</td>
</tr>
<tr>
<td>National programme</td>
<td>Framework of National Health Research Programme of the Ministry of Health</td>
</tr>
<tr>
<td>Funding commitment</td>
<td>1.0 Mio. €</td>
</tr>
<tr>
<td>Anticipated number of fundable project partners</td>
<td>~ 4</td>
</tr>
<tr>
<td>Maximum funding per grant awarded to a project partner</td>
<td>~ 0.25 M€</td>
</tr>
<tr>
<td>Eligibility of projects duration</td>
<td>Up to 3 years</td>
</tr>
<tr>
<td>Eligibility of a partner as a beneficiary institution</td>
<td>• Two researchers belonging to Italy - Ministry of Health eligible Institutions are allowed to apply in the same consortia. One consortia, two researchers, will share the amount of 250.000€.</td>
</tr>
</tbody>
</table>
### Guidelines for applicants JTC2021

- **Fundable:** ONLY IRCCS that are the Scientific Institutes for Research, Hospitalization and Health Care (Istituti di Ricovero e Cura a Carattere Scientifico pubblici e privati) and ISS (Istituto Superiore Sanità TBC) [National Institute of Health and ISS]
- **Non fundable:** University, research institute and other research institute

The simultaneous participation in proposals submitted in 2021 for different transnational research calls funded by the Ministry of Health is not allowed to Italian Principal Investigators, including WP leaders

---

<table>
<thead>
<tr>
<th>Eligibility of costs, types and their caps</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Direct Costs:</strong></td>
<td></td>
</tr>
<tr>
<td>Personnel (only temporary contracts) (max 50%);</td>
<td></td>
</tr>
<tr>
<td>Consumables;</td>
<td></td>
</tr>
<tr>
<td>Animals;</td>
<td></td>
</tr>
<tr>
<td>Equipment (only on hire);</td>
<td></td>
</tr>
<tr>
<td>Travel (max 10%);</td>
<td></td>
</tr>
<tr>
<td>Documentation (Max 1%)</td>
<td></td>
</tr>
<tr>
<td><strong>Indirect Costs:</strong></td>
<td></td>
</tr>
<tr>
<td>Overhead (max 10%);</td>
<td></td>
</tr>
<tr>
<td>Other indirect costs are not eligible</td>
<td></td>
</tr>
<tr>
<td>Not allowed transfer of eligible funds abroad</td>
<td></td>
</tr>
<tr>
<td>Subcontracts are allowed only upon approval, by presenting via WorkFlow - code ER a request together to the National eligibility form the latest 20 days before the deadline of the first stage.</td>
<td></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>National phase</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>In order to expedite the eligibility check process, the Ministry of Health will grant an eligibility clearance to the applicants prior to the submission of the proposals. To this end, it is mandatory that the applicants fill out and return a <a href="#">pre-submission eligibility check</a> form through IRCCS Scientific Directorate using WFR System before submitting their proposals to the Joint Call Secretariat. It is strongly recommended that the form, completed and duly signed, is returned at least 10 working days before the proposal submission deadline. Applicants will be sent a written notification of their eligibility status. The simultaneous participation in proposals submitted in 2021 for different transnational research calls funded by the <a href="#">Italian Ministry of Health</a> is not allowed to Italian Principal Investigators or other research team members.</td>
<td></td>
</tr>
<tr>
<td>Submission of financial and scientific reports at the national level</td>
<td>The mid-term and final scientific reports to the JCS are sufficient</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td>------------------------------------------------------------------</td>
</tr>
<tr>
<td>Further guidance</td>
<td>After the ENMIII JTC 2021 peer review process has been completed and the final (scientific) ranking list has been established and endorsed by the Call Steering Committee, the Ministry of Health will invite the principal investigators of the projects approved for funding to enter the formal national negotiations (according to national regulations). Submission of annual scientific and financial reports at the national level will be required according to the rules of the Ministry of Health. Further information on the rules of the Ministry of Health can be found at <a href="http://www.salute.gov.it">www.salute.gov.it</a> or requested to the national contact persons.</td>
</tr>
</tbody>
</table>
# LATVIA

<table>
<thead>
<tr>
<th>Funding Organisation</th>
<th>State Education Development Agency  <a href="http://www.viaa.gov.lv">www.viaa.gov.lv</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial funding pre-commitment</td>
<td>Latvian contribution to the call budget: 420,000 €. Upper funding limit is 70,000 EUR/year per project participant.</td>
</tr>
</tbody>
</table>
| National Contact Point for the 12TH call of EuroNanoMed | Dr. Linda Vecbiškena  
Tel.: (+371) 25153082  
Fax: (+371) 67814344  
E-mail: [linda.vecbiskena@viaa.gov.lv](mailto:linda.vecbiskena@viaa.gov.lv)  
State Education Development Agency  
Vaļņu street 1, Riga, LV-1050  
Latvia |
| Eligible institutions | Legal persons (as defined under the Latvian law) are eligible for funding, except natural persons:  
R&D institutions - research institutes, universities, higher education establishments, their institutes and research centres etc.  
Enterprises and companies.  
R&D institution (research institutes, universities, higher education establishments, research centres etc.) must be listed in the Registry of Research Institutions operated by the Ministry of Education and Science of the Republic of Latvia.  
Private entities must be registered in the Registry of Enterprises of the Republic of Latvia and provide most of its R&D&I activities in the Republic of Latvia. |
| Additional eligibility criteria | Information will be available at the national call and national contact point. |
| Eligible costs | Eligible direct costs for Latvian researchers:  
Personnel |
<table>
<thead>
<tr>
<th>Subcontracting (up to 20% of total direct costs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consumables, materials</td>
</tr>
<tr>
<td>Travel and Subsistence</td>
</tr>
<tr>
<td>• Equipment (only depreciation costs)</td>
</tr>
<tr>
<td>• Other</td>
</tr>
<tr>
<td>• Overheads:</td>
</tr>
<tr>
<td>• Up to 25% of eligible direct cost excluding subcontracting costs.</td>
</tr>
<tr>
<td><strong>LITHUANIA</strong></td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td><strong>Funding Organisation</strong></td>
</tr>
</tbody>
</table>
| **Initial funding pre-commitment** | Lithuania’s contribution to the call budget: 100 000 € - 150 000 €.  
For one three years project Lithuanian participants can require up to 150 000 € as a coordinator or up to 100 000 € as a mere partner. |
| **National Contact Point for the 12th call of EuroNanoMed** | Ms. Živilė Ruželė  
Tel.: (+370) 676 14383  
E-mail: zivile.ruzele@lmt.lt  
Research Council of Lithuania  
Gedimino Av.. 3, Vilnius  
Lithuania |
| **Eligible institutions** | Lithuanian research and education institutions: Universities, Research centres  
Public health care institutions: University hospitals, other public hospitals.  
SME (in collaboration with Lithuanian research and education institutions and health care institutions) meeting special criteria. More information will be available at the national call and national contact point. |
| **Additional criteria eligibility** | Information will be available at the national call and national contact point. |
| **Eligible costs** | Eligible direct costs for Lithuanian researchers:  
Personnel  
Subcontracting |
### Further guidance

This is not a comprehensive list of requirements for the Lithuanian participants. General Funding Rules of RCL (Lietuvos mokslo tarybos mokslo ir sklaidos projekty konkurxinio finansavimo bendrosios taisyklės) apply for this joint transnational call and special requirements that are listed in the call text in the Lithuanian language on the RCL website and ENM programme dedicated webpage.
### POLAND

| Funding Organisation | National Centre for Research and Development  
<table>
<thead>
<tr>
<th></th>
<th><a href="http://www.ncbr.gov.pl">www.ncbr.gov.pl</a></th>
</tr>
</thead>
</table>
| Initial funding pre-commitment | 1.200.000 €  
|                      | 2-6 projects tentatively envisaged to be funded; one project can require up to 200 000 €. |
| National Contact Point for the 11TH call of EuroNanoMed | National Centre for Research and Development  
|                      | Marcin Chmielewski  
|                      | e-mail: marcin.chmielewski@ncbr.gov.pl  
|                      | phone: +48 22 39 07 109 |
| Eligible institutions | Following entities are eligible to apply:  
|                      | Micro, Small, Medium and Large Enterprise; Research organizations. |
| Additional eligibility criteria | **IMPORTANT: A project consortium with Polish participation must include at least one Polish enterprise.**  
|                      | In addition, if two Polish participants take part in the project, they must form an internal national consortium to sign the contract with the National Center for Research and Development (NCBR). The above consortium should be created on the day of signing the national agreement at the latest. The Polish consortium counts as two project partners from Poland (it meets the limit on the number of participants from the same country, please see call text for details).  
|                      | Organization must be registered in Poland.  
|                      | For enterprises it is strongly advised to state in the Pre-proposal application form in table for Project coordinator/Project partner, in the row “Other information”: the KRS number of the enterprise and the size of the enterprise (micro/small, medium, large). |
| Eligible costs | The eligible costs shall be the following:  
|                | 1. **personnel costs** (researchers, technicians and other supporting staff to the extent employed on the research project);  
|                | 2. **operating costs** including costs of instruments, equipment, technical knowledge, patents, costs for buildings and land, costs of materials, supplies and similar products incurred directly as a result of the research activity; |
3. **cost of contractual research**, costs of consultancy and equivalent services used exclusively for the research activity; this cost type cannot account for more than 70% of all eligible costs of a project; the subcontracting can be obtained from consortium partner only in justified case, this need will be verified by a national experts panel;

4. **additional overheads** incurred indirectly as a result of the research project; that costs cannot account for more than 25% of eligible project costs and are counted as a multiplication by percentage given above and the rest of direct costs, excluding subcontracting (3); It means $4=(1+2)\times25\%$.

Funding quota of Polish participants can be up to 100% for universities or research organisations. In the case of enterprises, funding quota will be decided on a case-by-case basis depending on the size of the company, type of research/development, risk associated with the research activities and commercial perspective of exploitation.

<table>
<thead>
<tr>
<th></th>
<th>Large Enterprises</th>
<th>Medium Enterprises</th>
<th>Micro/Small Enterprises</th>
<th>Research organizations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundamental/Basic Research</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Industrial/Applied Research</td>
<td>Up to 50+15 (max 65%)</td>
<td>Up to 50+10+15 (max 75%)</td>
<td>Up to 50+20+15 (max 80 %)</td>
<td>Up to 100 %</td>
</tr>
<tr>
<td>Experimental development</td>
<td>Up to 25+15 (max 40 %)</td>
<td>Up to 25+10+15 (max 50%)</td>
<td>Up to 25+20+15 (max 60 %)</td>
<td>Up to 100 %</td>
</tr>
</tbody>
</table>

Only Industrial/Applied Research and Experimental Development will be funded. Other type of activities (e.g. coordination, dissemination, management) cannot be included into separated task. All eligible entities, invited to submit Polish proposal are obliged to use the rate of exchange of The European Central Bank dated on the day of opening the call.

**Further guidance**

Applicants are advised that this annex is for general guidance only. For more detailed rules and regulations please refer to the national call announcement and contact the National Contact Point.
### ROMANIA

| Funding Organisation | Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI)  
http://uefiscdi.gov.ro/ |
|----------------------|------------------------------------------------------------------|
| Initial funding     | 500.000 euro  
1-2 projects |
| pre-commitment      |                                                                  |
| National Contact    | Mihaela Manole (+40) 21 3023863  
mihaela.manole@uefiscdi.ro |
| Point for the 12TH  | UEFISCDI funding R & D projects, declared winner by participating in launched calls for ERANET projects – in  
call of EuroNanoMed   | Horizon 2020 Subprogramme |
| Eligibility criteria| Eligible entities for funding are universities, public institutions, R&D national institutions, joint-stock companies, SME's and  
Large companies, NGOs (associations, foundations, etc.), others.  
Funding rates vary in accordance with state aid legislation.  
For more information: https://www.uefiscdi.ro/pachet-de-informatii-suprogramul-3-2-orizont-2020  
Eligibility cost:  
a. Staff costs;  
b. Logistics expenses  
- Capital expenditure;  
- Expenditure on stocks - supplies and inventory items;  
- Expenditure on services performed by third parties cannot exceed 25 % of the funding from the public budget. The  
subcontracted parts should not be core/substantial parts of the project work;  
c. Travel expenses;  
d. Overhead (indirect costs) is calculated as a percentage of direct costs: staff costs, logistics costs (excluding capital costs  
and cost for subcontracting) and travel expenses. Indirect costs will not exceed 20 % of direct costs. |
**SLOVAKIA**

<table>
<thead>
<tr>
<th>Funding Organisation</th>
<th>Slovak Academy of Sciences (SAS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial funding</td>
<td>Up to 120,000 €</td>
</tr>
<tr>
<td>pre-commitment</td>
<td>Anticipated number of funded projects: 1</td>
</tr>
<tr>
<td></td>
<td>Maximal annual budget per project is 40,000 €</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Contact Point for the 12TH call of EuroNanoMed</th>
<th>Katarina BIBOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td>e-mail: <a href="mailto:bibova@up.upsav.sk">bibova@up.upsav.sk</a>, Phone: +421 2 5751 0136</td>
<td>Address: Slovak Academy of Sciences</td>
</tr>
<tr>
<td>Štefánikova 49</td>
<td>814 38 Bratislava</td>
</tr>
<tr>
<td>SLOVAKIA</td>
<td>SLOVAKIA</td>
</tr>
</tbody>
</table>

| Eligible institutions | Only research Institutes of Slovak Academy of Sciences are eligible organisations for funding (up to 100%). Applicants from other Slovak R&D centers have to cover the project costs from their own sources (Letter of Commitment). The teams outside of SAS (universities and/or another organisations) can be consortium members but not the coordinator of the consortium. |


<table>
<thead>
<tr>
<th>Eligible costs</th>
<th>Direct costs (DC) : Personnel (max. of 15 % of all DC ( ERA.Nets) or max. of 30% of all DC, if Slovak team is a coordinator of consortium ), Consumables, Equipment (max. 40% of DC) and Travel costs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Indirect costs (IC - overheads): max. 20 % of DC. Total eligible costs = DC + IC Training costs shall not be defined as a separate category, but included in other costs items.</td>
</tr>
</tbody>
</table>

| Further guidance | National phase: Submission of the proposal at the national level will be required in parallel to the international evaluation. The submission will be carried out once the international evaluation and the ranking list have been performed and endorsed by the EuroNanoMed II Call Steering Committee (CSC) and the Slovak project partner |

---

Guidelines for applicants JTC2021
has been informed by the project consortium coordinator and invited by SAS to submit the proposal to it (Formular MVTS). The Presidium of SAS makes the final decision for funding of selected projects.

- Web site: http://www.sav.sk/
- Act of February 19, 2002 on the Slovak Academy of Sciences,
- Financial rules for awarding SAS grants for research projects in frame of ERA.Net Programme for research institutes of SAS
- Principles of allocation of funds for the institutes of SAS to support projects in the field of international scientific cooperation

For more information please contact the NCP
## SPAIN (CDTI)

| Funding Organisation | Centro para el Desarrollo Tecnológico Industrial, E.P.E. (CDTI)  
http://www.cdti.es |
|----------------------|---------------------------------------------------------------|
| Initial funding      | EUR 500,000 (*)  
pre-commitment       | 3-5 projects tentatively envisaged to be funded |
| National programme   | R+D+i Internationalisation Programme  
| National Contact Point for the 12\textsuperscript{TH} call of EuroNanoMed | Marina Sopeña Escalona  
marina.sopena@cdti.es  
(+34) 91 581 56 07 |
| Eligibility criteria | Eligible entities: for-profit companies (being large or SME) established and carrying out R&D activities in Spain. Other entities such as universities, public research institutions, technological centres, and other private non-profit institutions could participate under subcontracting by Spanish companies (provided that, the entity or respective researcher is not requesting funding simultaneously from AEI-MINECO or ISCIII for the same activities). Eligible activities: technology-based industrial research and/or experimental development activities (in accordance with the definitions of EC Regulation nº651/2014), representing outstanding scientific-technical quality and high innovative potential. The Spanish part of the proposed work plan must be developed in Spain. Management and dissemination-related activities are explicitly excluded for funding.  
- Project duration: 12 to 36 months.  
- Project budget: The minimum eligible budget amounts to €175,000 per partner (this figure applies to the partner budget not the requesting funding).  
- Eligible costs:  
  - Personnel (intended exclusively for the RTD activities within the project). |
- Instrument and equipment costs, to the extent and during the period in which they are used for the RTD activities of the research project.
- Contractual research costs, technical knowledge and patents bought or licensed from outside sources at market prices, and costs for consulting and equivalent services intended exclusively for the research activity.
- Other operating expenses, including costs for material, supplies and similar products, which result directly from the RTD activities of the research project; project audit (when applicable); Overheads. Management & dissemination-related activities are not eligible for funding.

The detailed description is available on CDTI website:


- CDTI Funding: will be based on a financing package, entailing soft loans (up to 75% of the eligible budget, 85% in exceptional cases) with a non-repayable part, up to 33% of the loan. The available budget for the non-repayable part amounts to € 500,000.

- Specific financial conditions for ensuring the beneficiary’s solvency could be required according to CDTI funding rules. CDTI will avoid double funding, and will not finance projects, or parts of projects, that have been already funded through other national, transnational or EU calls. CDTI will be responsible for making the final decision regarding the awarding of funds to those Spanish applicants aiming to receive funding from CDTI, taking fully into account the assessment of the national full proposal, the transnational evaluation of the collaborative project, the previous funds received by the participants for other related projects, the fulfilment of eligibility and funding rules, and the financial resources available. Further information is available on:

http://www.cdti.es/index.asp?MP=100&MS=802&MN=2&r=1920*1080
| • National application: applicants requesting funding from CDTI must submit a formal proposal via the CDTI electronic submission system ([https://sede.cdti.gob.es](https://sede.cdti.gob.es)). The proposal must include a detailed description, in Spanish Language, of the activities to be undertaken by the applicant and their respective budget. Further guidance will be published on CDTI website. Applicants must indicate their VAT (CIF) number in all their respective applications (both international and national).

Applicants are strongly advised to check the detailed information available on the CDTI website and to contact the NCP for getting advice about national funding rules before submitting a proposal. |
### SPAIN (ISCIII)

<table>
<thead>
<tr>
<th>Funding Organisation</th>
<th>National Institute of Health Carlos III (ISCIII)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://www.isciii.es">www.isciii.es</a></td>
</tr>
<tr>
<td>National Funding Programme</td>
<td>Acción Estratégica en Salud (AES 2021)</td>
</tr>
<tr>
<td>Initial funding pre-commitment</td>
<td>1.000.000</td>
</tr>
<tr>
<td></td>
<td>6-8 projects tentatively envisaged to be funded</td>
</tr>
<tr>
<td>National Contact Point for the 12th call of</td>
<td>Astrid Valencia Quiñónez</td>
</tr>
<tr>
<td>EuroNanoMed</td>
<td>Email: <a href="mailto:ma.valencia@isciii.es">ma.valencia@isciii.es</a></td>
</tr>
<tr>
<td></td>
<td>Tel: (+34) 91 822 2227 / (+34) 685 594 988</td>
</tr>
<tr>
<td>Maximum funding per awarded Spanish project</td>
<td>• Regular (24-36 months):</td>
</tr>
<tr>
<td>partner</td>
<td>Up to 175,000 € per partner (overheads included) Up to 250,000 € per coordinator (overheads included). Additional 50,000 € could be granted if there is another industrial partner funded by CDTI in the consortium (i.e. up to 225,000 € as partner, up to 300,000 € as coordinator)</td>
</tr>
<tr>
<td></td>
<td>• Short collaborative projects (12-24 months):</td>
</tr>
<tr>
<td></td>
<td>Up to 100,000 € per partner (overheads included) Up to 150,000 € per coordinator (overheads included). Additional 50,000 € could be granted if there is another industrial partner funded by CDTI in the consortium (i.e. up to 150,000 € as partner, up to 200,000 € as coordinator)</td>
</tr>
</tbody>
</table>
| Eligible Institutions | - Hospitals, primary health care settings or public health administration of the Spanish National Health System (SNS)  
These institutions may manage research via a foundation regulated in accordance to the Spanish Act 50/2002, of December 26th (a copy of the foundation’s statutes may be submitted).  
- Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS)  
Accredited according to the RD 339/2004, of February 27th or RD 279/2016 (These institutions may manage research via a foundation regulated according to the Spanish Act 50/2002, of December 26th)  
- CIBER or CIBERNED  
Team members applying to the call must be from at least 2 groups belonging to CIBER in 2 different home institutions and one of these two should be a Hospital, primary health care setting or public health administration of the Spanish National Health System (SNS) or Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS). Please contact Cristina Rodríguez (cristina.rodriguez@ciberisciii.es) for more information related to CIBER’s eligibility and José de Arriba (jdearriba@ciberned.es) for CIBERNED’s.  
- Academia or Other Research Centers. These entities can only participate if they apply together with Hospitals, primary health care settings or public health administration of the Spanish National Health System (SNS) or Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS). It is not allowed to apply independently, thus there must be two beneficiary Spanish institutions in the same proposal.  

**NOTE:**  
- Applicants from ISCIII are allowed. Eligibility criteria from AESI 2021 apply.  
- Same institution cannot participate with more than one partner in the same project proposal.
### Additional eligibility criteria

- Grants are awarded for a maximum of 3 years in regular projects and 2 years for short collaborative projects.
- Due to administrative and legal regulations, the National Institute of Health Carlos III declares 30th of September 2021 as national deadline for the decision on fundable project consortia which include Spanish partners to be funded by ISCIII. Any concerned applicant in a proposal for which no final decision has been made by the deadline, could be declared not fundable by ISCIII.

**NOTE:** Researchers with ongoing EuroNanoMed projects in 2022 cannot apply to the current call unless the alive project or the new application is as coordinator.

### Eligibility of PI and team members

- Principal Investigators (PI) can only participate in one project proposal per call.
- PI and all members of the research group must belong to the eligible institution or be affiliated to CIBER, CIBERNED or an IIS.

**Excluded** personnel as Principal Investigator (PI):

- Those undergoing a postgraduate training in Health Specialization (MIR, FIR, QIR, BIR, PIR)
- Those undergoing research training (e.g. PhD students, or “Río Hortega” contracts)
- Researchers contracted by a RETIC.
- Those undergoing postdoctoral training (e.g. “Sara Borrell” or “Juan de la Cierva” contracts)

### Eligible costs

Personnel costs for temporary employment contracts (scholarships are not eligible) according to AES 2021. Current costs, small scientific equipment, consumables, disposable materials, traveling expenses and other costs than can be justified as necessary to carry out the proposed activities. Overheads according to AES 2021.

### National phase

- National applications will be required by ISCIII. National submission period will be published in the AES 2021 under the call for “International Joint Programming Projects” (Proyectos de Programación Conjunta Internacional). Spanish Applicants should periodically check the web page of ISCIII. ISCIII may not send invitations to the mandatory national phase.
### Mandatory acknowledgment
Any publication, data base, product or event protected with IPR or not, resulting from the granted project must acknowledge “Award no. XX by ISCIII through AES 2021 and within the framework of EuroNanoMed” even after the end of the project.

### Requirements on data and repositories
- Researchers funded by ISCIII must make public the human genomic data, as well as relevant data (phenotype and exposition data) generated inside the funded project and will use open access repositories. Researchers must also make public all the necessary information for the interpretation of these genomic data, including lab protocols, data instruments survey tools. Regarding genomic data it is understood: association of complete genomes (GWAS), matrixes of de polymorphism of a single nucleotide (SNP) and sequence of genome, and transcriptomic, metagenomic, epigenomic and gene expression data. The researchers whose projects are funded by ISCIII are recommended to store their scientific data at the “ELIXIR Core Data Resources” or if non-European repositories or data bases they must be certified by ELIXIR or the US National Center for Biotechnology Information (NCBI).
- ISCIII may no fund project that requires the construction of new repositories without decommissioning plans or ensured sustainability after the project’s end.

### Requirements for clinical studies
- Spanish groups participating in a proposal performing a clinical study are encouraged to contact and include as members of the team personnel from the Platform of Clinical Research Unit (Unidades de Investigación Clínica y Ensayos Clínicos - UICEC) of their institutions. Currently, it is under assessment the ISCIII’s platform that will support Non-Commercial Clinical Research over the period 2021-23, and that it is expected to be the scientific node of the EU Clinical Trials Network (ECRIN-ERIC). Once the call is awarded, we will update the relevant contact information within these guidelines.
TAIWAN

|----------------------|----------------------------------------------------------|
| Initial funding pre-commitment | 500,000 €  
Anticipated number of funded research groups: 1-2  
Maximum funding per project is 100,000 EUR/year (about NTD3,000,000).  
The decision regarding to the exact amount is subject to the result from the review; the review committee decides whether to fund the project and the amount. |
| National Contact Point for the 12th call of EuroNanoMed | Ching-Mei Tang  
E-Mail: cmtom@most.gov.tw  
Phone: +886-2-2737-7557 |
| Eligible institutions | In compliance with the MOST’s regulation ‘Operation Guidelines for MOST Research Grants’:  
• Applicant institutions (i.e., research conducting institutions) shall be approved by MoST to be eligible recipients of subsidisation in accordance with the ‘Operation Guidelines for Institutions Applying for MOST Grants’.  
• The eligible institutions are classified into three categories as follows:  
  1. Taiwanese public/private colleges and universities.  
  2. Taiwanese public/private research institutions  
  3. Taiwanese Medical institutions |
| Additional eligibility criteria | The standard funding policy and eligibility rules set by the Ministry of Science and Technology applied. |
| Eligible costs | Personnel, Consumables, Hosting expenses for foreign researchers, Travel expenses for international destinations-joint research  
MOST budget information, please refer to: [https://www.most.gov.tw/most/attachments/920c4b8e-21d4-4d2b-b603-5602690c575e](https://www.most.gov.tw/most/attachments/920c4b8e-21d4-4d2b-b603-5602690c575e) |
### Further guidance

- No official national application is needed in the pre-proposal or full proposal phase. But must notify the national contact person in the Ministry of Science and Technology of your submission to the joint transnational call via email, together with your application as an attachment.

- Please note that Taiwanese project partners shall submit a proposal to the MOST for national financing after the project has been selected and approved for funding through the Biodivrestore evaluation and selection process.

- For details of national application procedure, please refer to the joint-call announcement on the MOST’s website: [https://www.most.gov.tw/ch/academic](https://www.most.gov.tw/ch/academic) for more information.
**TURKEY**

| Funding Organisation | The Scientific and Technological Research Council of Turkey (TUBITAK)  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://www.tubitak.gov.tr">www.tubitak.gov.tr</a></td>
</tr>
</tbody>
</table>
| National Funding Programme | ARDEB 1071 - Support Programme for Increasing Capacity to Benefit from International Research Funds and Participation in International R&D Cooperation  
| Purpose: | development of new knowledge, solution to technological problems with scientific interpretations, improving/advancing current situation on the project topic, improving international cooperation. Projects in which partner from Turkey is only responsible for demonstration actions cannot be supported by TUBITAK.  

| Initial funding pre-commitment | Initial funding pre-commitment: 450.000 € (TBC)  
|--------------------------------|-------------------------------------------------------------------------------------------------|
|                                | **2-3 projects** tentatively envisaged to be funded.  
|                                | If there is more than one Turkish partner in a single transnational project, these partners should submit a joint national application under TUBITAK 1071 programme via project application system (uidb-pbs.tubitak.gov.tr) of TUBITAK.  

| Funding Rates: | **Universities (public and private), research institutes and public institutions**: %100 of the approved budget  
|----------------|---------------------------------------------------------------|
|                | **Large-size Enterprises**: %60 of the approved budget  
|                | **Small and Medium-size Enterprises**: %75 of the approved budget  

| National Contact Point for the 12th call of EuroNanoMed | Mahmut Özer E-mail: mahmut.ozer@tubitak.gov.tr  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tel: (+90) 312 298 12 08</td>
</tr>
</tbody>
</table>
**Guidelines for applicants JTC2021**

<table>
<thead>
<tr>
<th>Eligible institutions</th>
<th>Universities (public and private), research institutes, public and private corporations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Eligibility of PI and team members</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Principal Investigator* (PI) from university should have a PhD degree,</td>
</tr>
<tr>
<td>- PIs working in a public institution or a private corporation and researchers/advisors should have an undergraduate diploma,</td>
</tr>
<tr>
<td>- PI should be the permanent staff of the organization making the project proposal,</td>
</tr>
<tr>
<td>- PI, researchers (Co-PI) and advisors should reside and work in Turkey (Foreign nationals can be PI/researcher in the projects if they are working in an organization in Turkey),</td>
</tr>
<tr>
<td>- A researcher should have a contribution of at least 10% of the project workload,</td>
</tr>
<tr>
<td>- An advisor is allowed if the project requires special expertise on a specific subject. The number of advisors in a project is limited to the number of specific subjects in the project. The role of advisor in the projects should be explained in detail in the project proposal.</td>
</tr>
</tbody>
</table>

*University presidents and vice presidents, surgeon generals, vice surgeon generals, hospital presidents, institution/company presidents, and institution/company vice presidents are not allowed to be PI. For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.*
| Eligible costs | Eligible types of funding under this programme are limited to personnel costs, travel and subsistence, equipment, consumables and consultantship/services. Projects intended to build infrastructure cannot be supported. 

**For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum duration of projects</td>
<td>36 months for Regular Collaborative Projects and 12 to 24 months for Short Collaborative Projects</td>
</tr>
</tbody>
</table>
| National phase | Project coordinator of consortium must send English application form to call secretariat via online application tool. At the same time, project coordinator of Turkish team in the consortium must make 1\textsuperscript{st} stage national application via project application system (uidb-pbs.tubitak.gov.tr). If the Turkish team is funded after the 2\textsuperscript{nd} stage of international evaluation, they should then make 2\textsuperscript{nd} stage national application. 

**For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.** |
| Other Important Issues | For Short Collaborative Projects, it should be taken into consideration by applicants that certifications, patenting, licensing and commercializing activities are not supported by 1071 programme. 

Project coordinator, researchers and advisors must be registered to “Researcher Information System-ARBİS (arbis.tubitak.gov.tr)” and their info must be updated. 

Field studies in abroad cannot be supported. 

There should not be any running or concluded projects of research team with similar content of the proposed project. 

If works defined in proposal requires ethical committee certificate or legal/private permission, these permission documents in required format must be sent to TUBITAK for the funded projects. |
<table>
<thead>
<tr>
<th>Further guidance</th>
<th>Any publication resulting from the granted projects must acknowledge TUBITAK funding even after the end of the project.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.</strong></td>
</tr>
<tr>
<td></td>
<td>In addition to the national funding regulations provided herewith, all Turkish applicants are strongly recommended to check the announcements regarding this call under the official website of TUBITAK for the conditions of funding, and they are strongly advised to reach the Turkish national contact person before the application.</td>
</tr>
</tbody>
</table>
ANNEX 3: TECHNOLOGY READINESS LEVELS (TRL)

- TRL 1 – basic principles observed
- TRL 2 – technology concept formulated
- TRL 3 – experimental proof of concept
- TRL 4 – technology validated in lab
- TRL 5 – technology validated in relevant environment (industrially relevant environment in the case of key enabling technologies)
- TRL 6 – technology demonstrated in relevant environment (industrially relevant environment in the case of key enabling technologies)
- TRL 7 – system prototype demonstration in operational environment
- TRL 8 – system complete and qualified
- TRL 9 – actual system proven in operational environment (competitive manufacturing in the case of key enabling technologies; or in space)
ANNEX 4: GUIDELINES FOR RESPONSIBLE RESEARCH AND INNOVATION (RRI) IN PROPOSALS TO EURONANOMED III

This RRI guideline is to give a short introduction to RRI as concept and provide sources for more information. It also presents one possible way of thinking about RRI and introducing these reflections and RRI measures into a project proposal in nanomedicine.

Two key objectives for the ERA-NET for nanomedicine (EuroNanoMed III) are to:

1. Encourage the nanomedicine community to adopt RRI, HSE and ensure alignment with current regulatory requirements.
2. Train funded researchers on:
   - Translation processes (NOBEL-PROJECT might be helpful here)
   - Responsible Research and Innovation (RRI), including co-creation, co-design and co-production
   - Regulatory aspects

What is RRI?
In a nutshell RRI is:
- Involving societal actors in science and innovation throughout R&I processes to better-align their orientation with the values of society.
- In Horizon 2020, RRI is described as a broad umbrella connecting different aspects of the relationship between R&I and society: public engagement, open access, gender equality, science education, ethics, and governance.

In the EU Programme for Research and Innovation 2014-2020, Horizon2020, RRI is a cross-cutting issue, actions are also promoted via ‘Science with and for Society’. Here is the H2020 definition of RRI, including public engagement, open access, gender, ethics, science education.

More recently, RRI has been articulated as co-creation, co-design and co-production: methodologies in which projects are structured to include stakeholders from the outside (e.g. users or interest groups) with the expertise of the social sciences and humanities (SSH). This RRI Movie by RRI Tools describes the idea well also includes a broad RRI-toolbox.

ENM’s Joint Transnational Call 2020 call text says the following: "Projects are required to discuss and respond to Responsible Research and Innovation (RRI) aspects, including co-creating, co-design and co-production. Projects are required to include a plan to disseminate results/outcomes and how to achieve higher levels of technological readiness."
How can you include RRI in your proposal?

ENMIII’s philosophy is to have RRI as an integrated part of the project involving all project participants. This means that the approach taken should be specific to the project. While RRI may focus on broadly recognised issues, they should not be approached in a generic way.

Developing a shared understanding of the project’s RRI aspects as early as possible is really important. This will mean having conversations about their importance, action that is agreed upon, and what learning and adoption can occur throughout the project.

How this RRI content is adopted (e.g. who will be responsible for what work) in the proposal is project dependent. For example, RRI can be organised a cross-cutting part of the project or a separate work package. RRI in the project needs to be coordinated.

Please be aware that these guidelines and reflections neither represent the only RRI approach nor a complete list of examples of measures when implementing RRI in nanomedicine proposals. If you are aware of other tools or infrastructures relevant for RRI implementation in research and innovation projects in nanomedicine, please inform cam[at]rcn.no.

The following list provides examples of different RRI perspectives applicable for nanomedicine research projects (including ethical and safety issues). Choose those points relevant for your project.

1. Involve stakeholders of relevance to the project (e.g. clinicians, patient interest groups) at the earliest possible stage, to pursue co-creation, co-design and co-production methodologies.
   a. Co-design methodologies are important to generate trust but these stakeholders may also have knowledge about the social, environmental or commercial problem you are trying to address in your project.
   b. Think also about the appropriate timing of different stakeholders’ inclusion: certain kinds of knowledge may be more useful than others at different points of your project. (e.g. Doctors, physicians and patient groups early in the process with industry and investors at a later stage.)
   c. Think about how the involvement of these stakeholders and their knowledge can be formalised within your project. This may include a specific point in the middle of your project for reflection to occur, which may require your project to briefly pause, integrate this knowledge and potentially change course.
   d. It will likely be valuable (but not obligatory) to include expertise beyond the natural and physical sciences – such as social scientists, anthropologists or philosophers. They will be able to provide methodologies to address key challenges, such as the risk of hype and expectations of patients wanting treatment.

2. Involve all partners and participants in ongoing consideration of RRI throughout the project period. Remember to disseminate results/outcomes and publish via open science channels if possible. Involve RRI experts in project implementation, if appropriate.

3. Reflect on/consider adapting your choice of research methods regarding, for example:
   - ethical issues,
   - in vivo/in vitro experiments,
• use of new approaches such as “Safer by Design”.
• Are there ways that your project can advance common practices on these issues?

4. Address **environmental impacts and sustainable solutions** by including, for example:
   • lifecycle analysis,
   • ecotoxicology studies,
   • nanocharacterisation at the European Nanomedicine Characterisation Laboratory (EU-NCL).

5. Show how the project (and product) **satisfy requirements for production safety and efficiency** by, for example:
   • addressing health, safety and environment (HSE) issues;
     - using the competence achieved by the BIORIMA project that aims to develop an Integrated Risk Management (IRM) framework for (nano)biomaterials (NBM) used in Advanced therapy medicinal products (ATMP) and Medical device (MD);
     - using the EU NanoSafety Cluster
   • using the resources and knowledge from former pilot lines in your project, when relevant:
     - NanoPilot – A pilot plant for the production of polymer-based nanopharmaceuticals in compliance with good manufacturing practice (GMP) (finished);
     - Nanofacturing – A multiple-scale, manufacturing platform to support the extensive pipeline of nanopharmaceutical products being developed in Europe (finished);

6. Ensure that the medicine or device in the body is a **safe product with clear benefits for the patient** by, for example
   • listening to/satisfying user needs and safety concerns,
   • involving regulatory affairs professionals (toxicity tests, etc.),
   • communicating with regulatory entities (the Food and Drug Administration (FDA) or the European Medicines Agency (pharmaceuticals and medical devices), etc.

7. **Consider who will benefit and how these benefits can be delivered**
   • Does your project address a specific problem or need?
   • Does your framing of the problem fit with other people’s understanding of it? Can you gain access to these alternative framings?
   • In addition to societal benefits, also consider benefits to the research community through the generation of knowledge, access to infrastructure, the creation of networks and funding.
• Consider the appropriate form of intellectual property in your project. Is it possible to adopt looser property rights than normal to broaden access? (See, e.g. the Open MTA.)

• Could commercial or non-commercial organisations benefit from your research? How?

• Consider also the risks and ways that these can be ameliorated. For instance, what are the risks of potential risks of data being released? How can you take care to ensure these data are interpreted appropriately?

Do these reflections and include measures as early as possible to design the project as relevant (for society) as possible. This can avoid the project to end in a blind road or having to start over again almost from scratch.

All these points can also be relevant to discuss in the light of the UN Sustainable Development Goals (SDG).
ANNEX 5: DEFINITION OF EARLY CAREER RESEARCHERS (ECRS)

ECRs are defined as per the regulations of the European Research Council criteria for starting grants. In short, the researcher must have been awarded their first doctoral degree (PhD) **two to seven years prior to the pre-proposal submission deadline** of the EuroNanoMed III JTC 2021. However, there is no need to attach additional documentation when submitting the project proposal. Extensions to this period are allowed (with documentation) in the case of reasonably justified career breaks:

- For maternity: the effective elapsed time since the award of the first PhD/MD will be considered reduced by 18 months for each child born before or after the PhD/MD award
- For paternity: the effective elapsed time since the award of the first PhD/MD will be considered reduced by the actual amount of paternity leave taken for each child born before or after the PhD/MD award
- For long term illness (over ninety days), clinical qualification or national service the effective elapsed time since the award of the first PhD/MD will be considered reduced by the documented amount of leave taken for each event which occurred after the PhD/MD award

For medical doctors (or applicants holding a degree in medicine), an MD is not by itself considered equivalent to a PhD award. To be considered an ECR, these applicants must provide the certificates of both a medical doctor degree and a PhD, or proof of an appointment that requires doctoral equivalency (e.g. post-doctoral fellowship or professorship appointment). MD applicants that do not hold a PhD must have been awarded their MD **four to nine years prior to the pre-proposal submission deadline**. For medical doctors who have been awarded both an MD and a PhD, the date of the earliest degree that makes the applicant eligible will be used to calculate eligibility. Extensions to this period will be given (with documentation) for clinical training periods up to a maximum of four years.

Please note that in some countries MD may not be equivalent to PhD but equivalent to Bachelor of Medicine or Bachelor of Surgery. Doctoral or equivalent level, are designed primarily to lead to an **advanced research qualification**. For more details, you can see the International Standard Classification of Education (ISCED) of the UNESCO (page 59)


The following dates must be provided by Early Career Researchers so that their eligibility can be evaluated according to their respective regional/national regulations. **This information must be present in the CV in the pre- and full proposal forms.**
Medical doctors with PhD
Medical Studies: indicate dates (start and end) of your studies (year and month)
End of studies: indicate date of your medical certificate
PhD Time: indicate dates (start and end) of your PhD time (year and month)
PhD: indicate date of your PhD certificate
Appointment: indicate dates (start and end) of the appointment that requires doctoral equivalency (e.g. post-doctoral fellowship or professorship appointment), only if applicable

Medical doctors without PhD
Medical Studies: indicate dates (start and end) of your studies (year and month)
End of studies: indicate date of your certificate
Appointment: indicate dates of the appointment that requires doctoral equivalency (e.g. post-doctoral fellowship or professorship appointment)

Other Early Career Scientists with PhD
Studies: indicate dates (start and end) of your studies (year and month)
End of studies: indicate date of your studies
PhD Time: indicate dates (start and end) of your PhD time (year and month)
PhD: indicate date of your PhD certificate

Other Early Career Scientists without PhD
Studies: indicate dates (start and end) of your studies (year and month)
End of studies: indicate date of your studies
Appointment: indicate dates of the appointment that requires doctoral equivalency (e.g. post-doctoral fellowship or professorship appointment)

Reasons for Extensions, if applicable
Clinical Training: indicate dates (start and end) of clinical training (year and month);
Parental leave: Women: number of children (1.5 years are given per child; in case of longer maternal leave, please indicate the exact dates); Men: indicate exact dates of paternal leave (per child)
Career Break: indicate dates (year and month) of other career breaks: long-term sick leave, compulsory military service, carer’s leave